Pakistan’s pharmaceutical sector witnessed a huge increase in profits last year, with revenues rising 78% to a record high of Rs42.2 billion, according to a report released today.
This significant financial upturn has been attributed to a combination of factors, including industry deregulation, improved pricing structure, and reduced operational costs.
The industry’s net sales also saw a significant growth, rising by fourteen percent to Rs365.7 billion, a growth linked to more favorable pricing.
According to reports, the support from the Special Investment Facilitation Council (SIFC) has been instrumental in positioning the nation”s pharmaceutical industry on a trajectory towards new heights of expansion.